Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 45 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Clostridium Difficle Colitis Clear all

Conditions: Clostridium Difficle Colitis, Clostridium Difficle Associated Disease
Interventions: Not listed
Lead sponsor: Maimonides Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Clostridium Difficile, Clostridium Difficile Infection, C Difficile Colitis
Interventions: fluoroquinolone preprescription authorization, Control; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: Not listed
Enrollment: 5,871 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 7
States / cities: Phoenix, Arizona • Moreno Valley, California • Rochester, Minnesota + 4 more

Conditions: Clostridium Enterocolitis, Pseudomembranous Colitis, Antibiotic-Associated Colitis
Interventions: Not listed
Lead sponsor: Michael E. DeBakey VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Clostridium Difficile-Associated Diarrhea, Clostridium Enterocolitis, Clostridium Difficile Diarrhea, Antibiotic-associated Colitis, Antibiotic-associated Diarrhea
Interventions: GT160-246; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 58
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more

Conditions: Active C. Difficile Colitis
Interventions: Microbiota Transplantation (FMT); Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2036
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Clostridioides Difficile Infection
Interventions: Ursodiol 500 MG; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Clostridioides Difficile Infection, Clostridium Difficile Infection, Clostridium Difficile Diarrhea, Clostridia Difficile Colitis
Interventions: Alanyl-glutamine; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 105 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: Charlottesville, Virginia • Roanoke, Virginia

Conditions: Clostridium Difficile-associated Diarrhea (CDAD)
Interventions: intravenous immunoglobulin G (IVIG), Placebo; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 4
States / cities: Pittsburgh, Pennsylvania

Conditions: Clostridium Difficile, Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
Interventions: Fecal Microbiota Transplant; Biological
Lead sponsor: Judith Kelsen; Other
Eligibility: 3 Years to 21 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Clostridium Difficile Colitis
Interventions: fecal microbiota; Biological
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Clostridium Difficile Colitis
Interventions: CRS3123, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Crohn's Disease, Ulcerative Colitis, Clostridium Difficile, Inflammatory Bowel Disease
Interventions: Blood and stool sample; Other
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Inflammatory Bowel Diseases, Clostridioides Difficile Infection
Interventions: Xylitol, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Clostridium Enterocolitis, Pseudomembranous Colitis
Interventions: Nitazoxanide; Drug
Lead sponsor: Daniel M. Musher MD; Federal
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Clostridium Difficile Infection Recurrence
Interventions: RBX2660; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 12
States / cities: North Little Rock, Arkansas • Camarillo, California • Hamden, Connecticut + 9 more

Conditions: Clostridia Difficile Colitis, Clostridium; Sepsis
Interventions: Bezlotoxumab, Normal Saline; Biological · Other
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Enterocolitis, Pseudomembranous Colitis, Antibiotic-associated Colitis
Interventions: Lactobacillus GG; Drug
Lead sponsor: Michael E. DeBakey VA Medical Center; Federal
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Clostridium Enterocolitis, Pseudomembranous Colitis, Antibiotic-Associated Colitis
Interventions: Not listed
Lead sponsor: Michael E. DeBakey VA Medical Center; Federal
Eligibility: Not listed
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Clostridium Difficile Infection, Ulcerative Colitis, Indeterminate Colitis
Interventions: Fecal Microbial Transplantation; Biological
Lead sponsor: Stony Brook University; Other
Eligibility: 7 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Clostridium Difficile Colitis
Interventions: Nu-Lytely; Drug
Lead sponsor: Ascension Health; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 1
States / cities: Grand Blanc, Michigan

Conditions: Clostridium Difficile
Interventions: Serum-derived bovine immunoglobulin/protein isolate (SBI), Placebo; Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 3
States / cities: Miami, Florida • Chicago, Illinois

Conditions: Recurrent Clostridium Difficile Infection, Clostridium Difficile Infection, CDI, C.Difficile Diarrhea, C. Diff Colitis, C.Difficile Colitis
Interventions: Vancomycin, Placebo; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 2
States / cities: Madison, Wisconsin • Milwaukee, Wisconsin

Conditions: Enterocolitis, Pseudomembranous, Diarrhea, Clostridium Difficile
Interventions: GT267-004 (tolevamer potassium sodium); Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 13
States / cities: Modesto, California • Honolulu, Hawaii • Maywood, Illinois + 10 more

Conditions: Clostridium Difficile Colitis
Interventions: FMT, placebo; Biological
Lead sponsor: MemorialCare Health System; Other
Eligibility: 1 Year to 21 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

Serum Vancomycin Levels in Patients Receiving Enteral Vancomycin

FQ Restriction for the Prevention of CDI

Vancomycin vs. Nitazoxanide to Treat Recurrent C. Difficile Colitis

A Study of GT160-246 Versus Vancomycin in Patients With Clostridium Difficile-Associated Diarrhea

Defined Fecal Microbiota Transplantation for Clostridium Difficile Diarrhea

Prevention of Recurrence of Clostridioides Difficile Colitis With Ursodeoxycholic Acid (UCDA) as a Supplement to Standard Therapy

Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT)

IVIG Versus Placebo for the Treatment of Patients With Severe C-Diff

Fecal Microbiome Transplant

Stool Transplants to Treat Refractory Clostridium Difficile Colitis

Phase I Trial of a Single Dose of CRS3123

Host Immune Response to Clostridium Difficile Infection in Inflammatory Bowel Disease Patients

Xylitol Use for Decolonization of C. Difficile in Patients With IBD

Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Infection

A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection

Comparing the Effectiveness of IV Bezlotoxumab Versus Placebo in Decreasing Morbidity and Mortality in Patients With Fulminant C. Diff Requiring Surgery.

Addition of Lactobacillus to Metronidazole in Treatment of CDAD

Association Between Response to Treatment of C. Diff Colitis and Anti-C.Diff Toxin Antibody

Fecal Microbial Transplantation for C. Difficile and/or Ulcerative Colitis or Indeterminate Colitis

Clostridial Infection and Oral Lavage -Improving Treatment Before Illness Becomes Severe

To Evaluate the Impact of SBI on C. Difficile in Hospitalized UC Patients

Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection

A Study to Assess the Safety, Tolerability, Effectiveness and Absorption of Exodif™ Tablets in Clostridium Difficile-associated Diarrhea

Stool Transplant in Pediatric Patients With Recurring C. Difficile Infection